Mini review · 13 Feb 2026
Conference abstractPublished 11 Jul 2022
LAG-3, a novel immune checkpoint in Chronic Lymphocytic Leukemia
University of Oviedo, Spain
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic lymphocytic leukemia (CLL) is characterized by an acquired immunosuppression and diminished anti-tumor immunity. Patients with CLL are clear candidates for novel immunotherapies, such as immune checkpoint blockade, that try to restore the patients’ immune activity to induce therapeutic responses. Nonetheless, the use of monoclonal antibodies targeting PD-1/PD-L1, which has demonstrated unprecedented clinical efficacy in the treatment of some advanced cancers, has obtained disappointing results in CLL. The profound immune dysfunction of this patients and the role of additional immune checkpoints in this immunosuppression may play a critical role in the low therapeutic response. In agreement, we have characterized novel inhibitory checkpoints, namely LAG-3, ILT2 and HVEM-BTLA, that may be novel therapeutic targets in this malignancy. Particularly, we showed that LAG-3 expression is profoundly dysregulated in CLL and is associated with adverse clinical, genetic and cytogenetics features, and poor outcome of patients. LAG-3 is also involved in the immunosuppression observed in these patients. In line with this, Relatlimab, a new anti-LAG-3 blocking antibody currently in clinical trials in CLL, was able to partially restore NK cell and T cell anti-leukemic activities favoring the depletion of leukemic cells ex vivo. The anti-leukemic effect of Relatlimab may be further potentiated by its combination with the immunomodulatory drug (IMiD) lenalidomide. This drug significantly boosted the activity of T cells and NK cells in CLL having a cooperative effect with Relatlimab in the elimination of leukemic cells. Altogether our data provide a rationale support to further investigate Relatlimab and IMiDs for the management of hematological malignancies.
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Hematology & Thromboembolic Diseases.
Opinion · 25 Dec 2025
Clinical Patterns and Systemic Implications of Thromboembolism
Opinion · 25 Dec 2025
Integrating Clinical Risk and Preventive Care in Thromboembolism Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Hematology & Thromboembolic Diseases
- SubjectHaematology
- BylineArticles whose byline prints “Segundo Gonzalez”
